BioDrugs

, Volume 32, Issue 1, pp 91–98 | Cite as

LY2963016 Insulin Glargine: A Review in Type 1 and 2 Diabetes

Adis Drug Evaluation
  • 139 Downloads

Abstract

Subcutaneous once-daily LY2963016 insulin glargine (LY insulin glargine) [Abasaglar® (EU); Basaglar® (USA)] has been approved in the EU as a biosimilar to reference insulin glargine (Lantus®), and in the USA as a follow-on biologic to reference insulin glargine, for use in patients with type 1 or 2 diabetes. Structural and functional characterization of LY insulin glargine in preclinical studies showed that it is similar to reference insulin glargine. In phase I euglycaemic clamp studies, LY insulin glargine demonstrated similar pharmacodynamic (including duration of action) and pharmacokinetic parameters to reference insulin glargine. In the phase III ELEMENT trials, LY insulin glargine and reference insulin glargine were noninferior to each other with respect to glycaemic control, indicating their equivalent efficacy, when administered with mealtime insulin in adults with type 1 diabetes or with oral antiglycaemic medications in adults with type 2 diabetes. LY insulin glargine was generally well tolerated, with a safety profile (including the risk of hypoglycaemia and immunogenicity) similar to that of reference insulin glargine and without any additional safety concerns identified. Basal insulin treatment status at baseline did not impact the relative efficacy, safety and immunogenicity of LY insulin glargine versus reference insulin glargine in the ELEMENT 1 and 2 trials. In conclusion, LY insulin glargine offers an additional basal insulin option for patients with type 1 or 2 diabetes, potentially at a lower cost.

Notes

Compliance with Ethical Standards

Funding

The preparation of this review was not supported by any external funding.

Conflict of interest

Yvette Lamb and Yahiya Syed are salaried employees of Adis/Springer, are responsible for the article content and declare no relevant conflicts of interest.

Additional information about this Adis Drug Review can be found at http://www.medengine.com/Redeem/FF98F0603768E31C.

References

  1. 1.
    International Diabetes Federation. Diabetes and cardiovascular disease: executive summary. 2016. http://www.idf.org/. Accessed 9 Jan 2018.
  2. 2.
    Dunn CJ, Plosker GL, Keating GM, et al. Insulin glargine: an updated review of its use in the management of diabetes mellitus. Drugs. 2003;63(16):1743–78.CrossRefPubMedGoogle Scholar
  3. 3.
    Heinemann L, Home PD, Hompesch M. Biosimilar insulins: guidance for data interpretation by clinicians and users. Diabetes Obes Metab. 2015;17(10):911–8.CrossRefPubMedPubMedCentralGoogle Scholar
  4. 4.
    Davies M, Dahl D, Heise T, et al. Introduction of biosimilar insulins in Europe. Diabet Med. 2017;34(10):1340–53.CrossRefPubMedPubMedCentralGoogle Scholar
  5. 5.
    Eli Lilly and Company. US prescribing information for Basaglar (insulin glargine injection), for subcutaneous use. 2016. http://pi.lilly.com/. Accessed 9 Jan 2018.
  6. 6.
    US FDA. FDA approves Basaglar, the first “follow-on” insulin glargine product to treat diabetes [media release]. 16 Dec 2015. http://www.fda.gov/.
  7. 7.
    European Medicines Agency. Abasaglar (previously Abasria): summary of product characteristics. 2016. http://www.ema.europa.eu/. Accessed 9 Jan 2018.
  8. 8.
    European Medicines Agency. Abasria CHMP assessment report. 2014. http://www.ema.europa.eu/. Accessed 9 Jan 2018.
  9. 9.
    Blevins TC, Dahl D, Rosenstock J, et al. Efficacy and safety of LY2963016 insulin glargine compared with insulin glargine (Lantus®) in patients with type 1 diabetes in a randomized controlled trial: the ELEMENT 1 study. Diabetes Obes Metab. 2015;17(8):726–33.CrossRefPubMedGoogle Scholar
  10. 10.
    Pollom RK, Lacaya LB, Ilag LL. Efficacy and safety between insulin glargine products (LY293016 and Lantus®) in patients with T2DM: the ELEMENT 5 study [abstract no. 963-P]. In: American Diabetes Association 77th Scientific Sessions. 2017.Google Scholar
  11. 11.
    Rosenstock J, Hollander P, Bhargava A, et al. Similar efficacy and safety of LY2963016 insulin glargine and insulin glargine (Lantus®) in patients with type 2 diabetes who were insulin-naive or previously treated with insulin glargine: a randomized, double-blind controlled trial (the ELEMENT 2 study). Diabetes Obes Metab. 2015;17(8):734–41.CrossRefPubMedGoogle Scholar
  12. 12.
    Eli Lilly and Company. A study of LY2963016 compared to Lantus® in adult participants with type 2 diabetes mellitus (ELEMENT 5) [ClinicalTrials.gov identifier NCT02302716] US National Institutes of Health, ClinicalTrials.gov. 2017. http://clinicaltrials.gov/. Accessed 9 Jan 2018.
  13. 13.
    Perez-Nieves M, Pollom RK, Delozier AM, et al. Adult low blood sugar survey (ALBSS) and insulin treatment satisfaction questionnaire (ITSQ) patient-reported outcomes (pros) in LY2963016 insulin glargine (LY IGlar) and lantus insulin glargine (IGlar) trials [abstract no. 2495-PO]. Diabetes. 2015;64(Suppl 1):A631.Google Scholar
  14. 14.
    Hadjiyianni I, Dahl D, Lacaya LB, et al. Efficacy and safety of LY2963016 insulin glargine in patients with type 1 and type 2 diabetes previously treated with insulin glargine. Diabetes Obes Metab. 2016;18(4):425–9.CrossRefPubMedPubMedCentralGoogle Scholar
  15. 15.
    Takahashi A, Chida D, Nishiyama H. The efficacy and safety of LY2963016 insulin glargine (LY IGlar) in Japanese patients with type 1 diabetes mellitus previously treated with Lantus insulin glargine (IGlar): a subgroup analysis of the ELEMENT-1 study: therapeutics of diabetes [abstract no. 0046]. J Diabetes Investig. 2016;7(Suppl 2):20.Google Scholar
  16. 16.
    Ilag LL, Deeg MA, Costigan T, et al. Evaluation of immunogenicity of LY2963016 insulin glargine compared with Lantus® insulin glargine in patients with type 1 or type 2 diabetes mellitus. Diabetes Obes Metab. 2016;18(2):159–68.CrossRefPubMedPubMedCentralGoogle Scholar
  17. 17.
    Pollom RK, Costigan T, Lacaya LB, et al. Similar efficacy and safety of LY2963016 insulin glargine and insulin glargine (Lantus®) in patients with T2D in age groups (< 65, ≥ 65 years). Can J Diabetes. 2016;40(5):S40.CrossRefGoogle Scholar
  18. 18.
    Eli Lilly and Company. A study in adults with type 1 diabetes (ELEMENT 1) [ClinicalTrials.gov identifier NCT01421147] US National Institutes of Health, ClinicalTrials.gov. 2014. http://clinicaltrials.gov/. Accessed 9 Jan 2018.
  19. 19.
    Eli Lilly and Company. A study in adults with type 2 diabetes (ELEMENT 2) [ClinicalTrials.gov identifier NCT01421459] US National Institutes of Health, ClinicalTrials.gov. 2014. http://clinicaltrials.gov/. Accessed 9 Jan 2018.
  20. 20.
    National Institute for Health and Care Excellence. Type 1 diabetes in adults: diagnosis and management. 2016. http://www.nice.org.uk/. Accessed 9 Jan 2018.
  21. 21.
    National Institute for Health and Care Excellence. Type 2 diabetes in adults: management. 2017. http://www.nice.org.uk/. Accessed 9 Jan 2018.
  22. 22.
    Chiang JL, Kirkman MS, Laffel LMB, et al. Type 1 diabetes through the life span: a position statement of the American Diabetes Association. Diabetes Care. 2014;37:2034–54.CrossRefPubMedGoogle Scholar
  23. 23.
    European Medicines Agency. LUSDANA 100 units/mL solution for injection in a pre-filled pen: summary of product characteristics. 2017. http://www.ema.europa.eu/. Accessed 9 Jan 2018.
  24. 24.
    Merck. Merck announces U.S. FDA grants tentative approval for LUSDANA™ Nexvue™ (insulin glargine injection, a follow-on biologic basal insulin [media release]. 20 Jul 2017. http://investors.merck.com/. Accessed 9 Jan 2018.
  25. 25.
    American Diabetes Association. Standards of medical care in diabetes. Diabetes Care. 2017;40(Suppl 1):S1–134.Google Scholar
  26. 26.
    Farfan-Portet M-I, Gerkens S, Lepage-Nefkens I, et al. Are biosimilars the next tool to guarantee cost-containment for pharmaceutical expenditures? Eur J Health Econ. 2014;15:223–8.CrossRefPubMedGoogle Scholar
  27. 27.
    Blair HA, Keating GM. Insulin glargine 300 U/mL: a review in diabetes mellitus. Drugs. 2016;76(3):363–74.CrossRefPubMedGoogle Scholar
  28. 28.
    Owens RA, Kahl SD, Ruan X, et al. The in vitro pharmacology of LY IGlar (LY2963016): a new insulin glargine product [abstract no. 1033-P]. Diabetes. 2015;64(Suppl 1):A265.Google Scholar
  29. 29.
    Bolli GB, Hahn AD, Schmidt R, et al. Plasma exposure to insulin glargine and its metabolites M1 and M2 after subcutaneous injection of therapeutic and supratherapeutic doses of glargine in subjects with type 1 diabetes. Diabetes Care. 2012;35:2626–30.CrossRefPubMedPubMedCentralGoogle Scholar
  30. 30.
    Kurtzhals P, Schäffer L, Sorensen A, et al. Correlations of receptor binding and metabolic and mitogenic potencies of insulin analogs designed for clinical use. Diabetes. 2000;49(6):999–1005.CrossRefPubMedGoogle Scholar
  31. 31.
    Sommerfeld MR, Müller G, Tschank G, et al. In vitro metabolic and mitogenic signaling of insulin glargine and its metabolites. PLoS One. 2010;5(3):e9540.CrossRefPubMedPubMedCentralGoogle Scholar
  32. 32.
    Guettier J-M. Center for drug evaluation and research: summary review (application number 205692Orig1s000). 2014. http://www.accessdata.fda.gov/. Accessed 9 Jan 2018.
  33. 33.
    Linnebjerg H, Lam EC, Seger ME, et al. Comparison of the pharmacokinetics and pharmacodynamics of LY2963016 insulin glargine and EU- and US-approved versions of Lantus insulin glargine in healthy subjects: three randomized euglycemic clamp studies. Diabetes Care. 2015;38(12):2226–33.CrossRefPubMedGoogle Scholar
  34. 34.
    Linnebjerg H, Lam EC, Zhang X, et al. Duration of action of two insulin glargine products, LY2963016 insulin glargine and Lantus insulin glargine, in subjects with type 1 diabetes mellitus. Diabetes Obes Metab. 2016;19(1):33–9.CrossRefPubMedPubMedCentralGoogle Scholar

Copyright information

© Springer International Publishing AG, part of Springer Nature 2018

Authors and Affiliations

  1. 1.SpringerAucklandNew Zealand

Personalised recommendations